Veradigm Inc. (MDRX) Veradigm Inc. is a global healthcare technology enterprise that delivers cutting-edge information technology platforms to a diverse client base, including healthcare providers, health plans (payers), and biopharmaceutical companies, operating across the United States and various international markets. For healthcare providers, the company offers a suite of integrated solutions designed to optimize operations. These include Practice Management software, AI-driven Patient Scheduling tools, and systems for Electronic Statements and Payments. Veradigm also provides comprehensive revenue cycle management, encompassing specialized services and a dedicated clearinghouse to streamline financial workflows. Furthermore, their electronic health records (EHR) portfolio features advanced options like ePrescribe with EPCS, Veradigm HER, and Practice Fusion HER, complemented by a robust Patient Engagement Platform. The firm extends its offerings to network partners through a variety of connectivity solutions. These comprise API integration tools such as Veradigm Connect and Veradigm App Expo, a Diagnostic Ordering and Resulting Network, a Channel Partner Program, and Veradigm ePrescribe Enterprise. Health plans and payers benefit from Veradigm's specialized solutions, which include sophisticated risk adjustment tools like Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics. They also provide quality management systems, including quality analytics and integrated risk adjustment and quality management features. Data exchange and coding solutions, such as eChart Courier, eChart Coder, and eChart Integration and Analytics, further enhance efficiency. Additionally, Veradigm offers provider engagement platforms like Veradigm Payer Insights and the comprehensive Veradigm Payerpath suite. For the biopharma sector, Veradigm supplies valuable real-world data solutions, including extensive health datasets and specialized registries for cardiology and metabolic conditions. This is coupled with real-world evidence platforms, such as the Real World Evidence Analytics Platform. Therapy-focused data is available for key areas like cardiovascular, central nervous system, metabolic, and immunology. The company also delivers Digital Health Media solutions. Established in 1986 and headquartered in Chicago, Illinois, Veradigm Inc. was previously known as Allscripts Healthcare Solutions, Inc., before rebranding to its current name in January 2023.
Sector: Services-Computer Integrated Systems Design
Industry: Medical - Healthcare Information Services
Veradigm Inc. OTC:MDRX Healthcare · Medical - Healthcare Information Services
All Press Release SEC Filings News
Press Release
Veradigm Product Portfolio Achieves HITRUST i1 Certification
Veradigm announced that a broad set of 16 solutions — including Veradigm EHR, Practice Fusion, and FollowMyHealth — achieved HITRUST i1 Certification for independently validated security controls.
The certification reflects independent assessment under the HITRUST Assurance Program and is intended to streamline customer security reviews and build client confidence.
The announcement is a modest positive for sales credibility but carries no quantified financial impact.
• 5d ago AI analysis › SEC Filing ⚠ 5
MDRX: 8-K · other
Veradigm furnished its September 2026 investor presentation in an 8-K (Item 7.01) ahead of appearances at the Jefferies Healthcare Services and Technology Conference on September 15 and the Deutsche Bank 2026 Healthcare Summit on September 16.
The deck discloses preliminary, unaudited expected 2025 revenue of $584-589 million split across three segments (Provider $463-467M, Payer $71-72M, Life Sciences ~$50M), alongside $120 million in cash and cash equivalents at year-end 2025 against $75 million of debt.
Veradigm says it filed its 2023 and 2024 Form 10-Ks on May 26, 2026, has the 2025 audit underway with a 10-K filing expected in the later part of 2026, and expects to relist its shares on a national exchange once current with filings; the stock currently trades as MDRX on the OTC Expert Market.
Management's 'reset, recover, reignite' strategy targets growth acceleration beginning in 2026, but the deck concedes revenue has been flat since 2022 and Provider EHR gross revenue retention sits at just 82%.
SEC 8-K • 1mo ago SEC Filing ⚠ 3
MDRX: 8-K · other
Veradigm disclosed in an Item 8.01 Form 8-K that one of its third-party vendors suffered a cybersecurity incident affecting data tied to a small number of the company's customers. An unauthorized party used credentials stolen from the vendor's environment to access a company API and download certain patient personal data, including in some instances Social Security numbers; no clinical or medical data was involved.
The company said the compromised credentials provided access only through that limited interface and did not reach its broader network, servers, databases, or other systems, and the incident caused no operational disruptions. Veradigm activated its incident response protocols, notified law enforcement, and is notifying affected customers and individuals while offering credit monitoring where applicable.
Veradigm has not yet determined the extent of potential liabilities but stated that, based on information currently available, it does not believe the incident is reasonably likely to have a material impact on its business, operations, financial condition, or results of operations. The filing flags legal, reputational, and financial risks including possible regulatory inquiries, litigation, or remediation costs.
SEC 8-K • 1mo ago Press Release ⚠ 1
Veradigm Announces Updated Presentation Time for Upcoming Investor Conference
Veradigm announced it will now present at the 2026 Jefferies Healthcare Services and Technology Conference on September 15 at 3:35PM CT, with a live webcast of the fireside chat available on its investor relations website.
The release is a scheduling update only and contains no financial results, guidance, or strategic news.
Veradigm provides clinical and revenue cycle solutions serving more than 20,000 provider practices and currently trades over the counter under the ticker MDRX.
• 1mo ago AI analysis › Press Release
Veradigm to Participate in Two Upcoming Investor Conferences
Veradigm CEO Don Trigg and CFO Christian Greyenbuhl will attend the Jefferies Healthcare Services and Technology Conference on September 15 for a fireside chat.
Management is also scheduled to participate in the Deutsche Bank 2026 Healthcare Summit in New York on September 16 for one-on-one meetings.
The company supports over 20,000 provider practices with clinical and revenue cycle solutions.
• 2mo ago AI analysis › SEC Filing ● Critical ⚠ 8
MDRX: NT 10-Q · late filing
Veradigm Inc. filed a Form 12b-25 notification on August 11, 2026 telling the SEC it cannot file its Form 10-Q for the fiscal quarter ended June 30, 2026 within the prescribed deadline.
The company remains stuck in a multi-year reporting backlog: its Q1, Q2 and Q3 2025 10-Qs, its 2025 Form 10-K, and its Q1 2026 10-Q are all delinquent, following Board determinations that financial statements for 2020, 2021 and 2022 could no longer be relied upon due to misstated revenue from internal control failures.
Veradigm was delisted from Nasdaq in April 2024 for failing to timely file periodic reports and hold an annual meeting, and the company offers no assurance on when the delinquent reports will be filed or whether it will ever return to the Nasdaq Global Select Market.
Risks flagged include potential deregistration under Exchange Act Section 12(b), possible additional material weaknesses from the pending FY2025 audit, putative securities class action and stockholder derivative lawsuits, and the terms of a $100 million senior secured term loan entered into in June 2025.
SEC NT 10-Q • 2mo ago SEC Filing
MDRX: 8-K · material agreement
Veradigm Inc. has extended the term of its Stockholder Agreement with Charles Myers and Jessica Myers to December 31, 2026.
The agreement governs Myers' rights as an observer of the company's board of directors, and the company stated that no further extensions are anticipated beyond this date.
SEC 8-K • 4mo ago SEC Filing ⚠ 3
MDRX: 8-K/A · leadership change
Veradigm Inc. filed an amended 8-K to disclose the specific terms of a consulting agreement with Leland Westerfield, its former Interim CFO, who will serve as a Strategic Financial Advisor through March 2027.
The agreement requires Westerfield to assist in the transition to new CFO Christian Greyenbuhl and, critically, to remediate identified material weaknesses in the company’s internal control over financial reporting.
Compensation includes a monthly fee of $45,937.50 for ten months and a $100,000 restricted stock unit award, contingent on Westerfield signing a general release of claims.
SEC 8-K/A • 5mo ago SEC Filing ⚠ 2
MDRX: 10-K · periodic report
Veradigm Inc. filed its Annual Report on Form 10-K for the fiscal years ended December 31, 2023 and December 31, 2024, on May 26, 2026. The filing includes standard certifications from Principal Executive Officer Donald Trigg and Interim CFO Leland Westerfield confirming the accuracy of the financial statements and internal controls.
The exhibits disclose the terms of Veradigm’s poison pill (Stockholder Rights Agreement), which expires on December 31, 2026, and includes a flip-in provision triggered if any person acquires 20% or more of the company’s shares without board approval. The exercise price for the rights is set at $32.00 per right.
Additionally, the filing includes an amendment to the separation agreement for former executive Tejal Vakharia, effective December 26, 2025, which accelerates the vesting of equity awards scheduled to vest within twelve months of termination. The company also lists its subsidiaries, including Allscripts Holdings, LLC and Practice Fusion, Inc.
SEC 10-K • 5mo ago AI analysis › Press Release ⚠ 5
Veradigm Files 2023 and 2024 Form 10-K
Veradigm filed its delinquent 2023 and 2024 Form 10-Ks with the SEC, marking a critical compliance milestone after a prolonged period of filing delays.
The filings reveal a sharp deterioration in 2024, with revenue falling to $594.4 million and a net loss of $291.6 million driven by a $108.2 million goodwill impairment and transaction costs.
Management provided preliminary 2025 guidance of $584M-$589M in revenue and reaffirmed its goal to file the 2025 10-K before year-end 2026 to facilitate a potential national exchange relisting.
• 5mo ago AI analysis › Press Release
Veradigm to Release Business Update May 26th and Host Investor Call May 27th
Veradigm announced it will release a business update after market close on Tuesday, May 26, 2026.
An investor conference call to discuss the update is scheduled for Wednesday, May 27, at 8:00 a.m. ET.
The release contains no specific financial data or strategic announcements, serving only as a scheduling notice for upcoming disclosures.
• 5mo ago AI analysis › SEC Filing ● Critical ⚠ 6
MDRX: NT 10-Q · late filing
Veradigm Inc. filed a Form 12b-25 notifying the SEC that it cannot file its Quarterly Report on Form 10-Q for the period ended March 31, 2026, without unreasonable effort or expense.
The company cites an inability to file due to a significant backlog of "Historical Late Filings," encompassing all required periodic reports for fiscal years 2023, 2024, and 2025, which stem from internal control failures and required restatements for 2020 and 2021.
As a consequence of these reporting failures, Veradigm was delisted from the Nasdaq Global Select Market in April 2024 and currently faces securities class action and derivative lawsuits.
SEC NT 10-Q • 5mo ago Press Release
Veradigm Launches Health Network Architecture to Level the Playing Field for Independent Practices
Veradigm announced the availability of its Health Network Architecture, a platform designed to give independent practices real-time visibility into clinical, financial, and operational data.
The solution connects disparate systems like EHR and practice management tools, enabling features such as real-time quality measure updates and automated prior authorizations.
General availability is expected in the coming weeks, with additional AI-powered capabilities rolling out throughout 2026.
• 5mo ago AI analysis › Press Release
Veradigm Survey: Independent Practices Rely on Technology to Stay Independent
Veradigm released results from a March 2026 survey of 360 independent practice leaders, finding that 79% view technology as critical to remaining independent.
The survey highlighted revenue cycle performance as a major focus area, with 68% of respondents reporting limited visibility into accounts receivable and 48% noting increased claim denials.
While 62% of practices feel prepared for value-based care models, 49% cite administrative requirements as their top barrier to participation.
• 5mo ago AI analysis › Press Release
Veradigm Receives KLAS 2026 Points of Light Award for Embedding SDOH Data in Provider EHR Workflows
Veradigm received the KLAS 2026 Points of Light Award for a collaborative initiative that embedded social determinants of health data directly into provider EHR workflows.
The project utilized the Veradigm Payer Insights platform to surface clinical reminders and connect providers to community resources, resulting in improved care gap closure rates.
CEO Donald Trigg emphasized that the award recognizes the value of collaboration between providers and payers to improve patient outcomes.
• 5mo ago AI analysis › Press Release
Veradigm Doubles India-Based Employee Footprint, Adds New Managing Director
Veradigm announced a major expansion of its Pune operations, effectively doubling office capacity to support rapidly growing teams.
Divesh Singla was appointed Managing Director of India Operations to accelerate the company's strategy and scale the Pune team.
The move reflects Veradigm's investment in an AI-fueled global workforce and leverages Pune's deep pool of skilled professionals for 24/7 client delivery.
• 5mo ago AI analysis › 
